Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
8.41
-0.08 (-0.94%)
Nov 4, 2024, 4:00 PM EST - Market closed
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for AMRX stock have an average target of 9.00, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 7.02% from the current stock price of 8.41.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 2, 2024.
Analyst Ratings
The average analyst rating for AMRX stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +42.69% | Oct 2, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $9 | Sell → Hold | Upgrades | $9 | +7.02% | Sep 6, 2024 |
| Barclays | Barclays | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +18.91% | Aug 13, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +18.91% | Aug 12, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $6.25 → $8 | Strong Buy | Maintains | $6.25 → $8 | -4.88% | May 6, 2024 |
Financial Forecast
Revenue This Year
2.81B
from 2.39B
Increased by 17.56%
Revenue Next Year
2.91B
from 2.81B
Increased by 3.23%
EPS This Year
0.61
from -0.48
EPS Next Year
0.71
from 0.61
Increased by 17.15%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.9B | 3.1B | 3.3B |
| Avg | 2.8B | 2.9B | 3.0B |
| Low | 2.7B | 2.7B | 2.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 21.6% | 10.1% | 13.7% |
| Avg | 17.6% | 3.2% | 2.9% |
| Low | 12.2% | -2.6% | -7.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.66 | 0.91 | 0.88 |
| Avg | 0.61 | 0.71 | 0.79 |
| Low | 0.57 | 0.49 | 0.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 49.9% | 23.5% |
| Avg | - | 17.2% | 10.5% |
| Low | - | -19.6% | 1.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.